Clinical Trial Update: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation [Phase 2]

View source ↗

Summary

ClinicalTrials.gov update describes a Phase II randomized study (APOLLO) comparing olaparib versus placebo after curative-intent therapy in patients with resect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Acinar Cell Carcinoma
• Pancreatic Adenocarcinoma
• Pancreatic Adenosquamous Carcinoma
• Pancreatic Cancer
• Pancreatic Squamous Cell Carcinoma

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma | Phase 2 | Status: RECRUITING